Terms: = Thyroid cancer AND APOBEC3B, ARP4, 9582, ENSG00000179750, DJ742C19_2, _phorbolin 3_, PHRBNL, FLJ21201, Q9UH17, bK150C2_2, APOBEC1L, ARCD3 AND Treatment
7869 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: A Bayesian network meta-analysis.
Liu X; Wong CKH; Wu T; Chan WWL; Woo YC; Lam CLK; Lang BHH
World J Surg; 2024 Feb; 48(2):393-407. PubMed ID: 38686801
[TBL] [Abstract] [Full Text] [Related]
3. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
[TBL] [Abstract] [Full Text] [Related]
4. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of the Craniopharyngioma Resection via Expanded Endoscopic Endonasal Transsphenoidal Approach in the treatment of Complex Craniopharyngioma and Its Effect on Pituitary Function and Complications of Patients.
Bu X
Ann Ital Chir; 2024; 95(2):192-199. PubMed ID: 38684506
[TBL] [Abstract] [Full Text] [Related]
6. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract] [Full Text] [Related]
7. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
8. Assessment of thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract] [Full Text] [Related]
9. Persistent hypercalcaemia associated with two pathogenic variants in the
Leszczyńska D; Szatko A; Latocha J; Kochman M; Duchnowska M; Wójcicka A; Misiorowski W; Zgliczyníski W; Glinicki P
Front Endocrinol (Lausanne); 2024; 15():1355916. PubMed ID: 38665259
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and safety of fibrin sealant application in patients undergoing thyroidectomy: a systematic review and meta-analysis.
Zheng X; Wang F; Su YC; Xu CY; Wang MZ
BMC Surg; 2024 Apr; 24(1):122. PubMed ID: 38658932
[TBL] [Abstract] [Full Text] [Related]
11. PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract] [Full Text] [Related]
12. Prevalence and impact of endocrine disorders in advanced metastatic cancer patients undergoing cancer-directed therapy: A prospective observational study.
Karna G; Sehrawat A; Karna S; Kant R; Sundriyal D; Karn S; Jha D
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2011. PubMed ID: 38644759
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials.
Zhao M; Li R; Song Z; Miao C; Lu J
Medicine (Baltimore); 2024 Apr; 103(15):e37655. PubMed ID: 38608050
[TBL] [Abstract] [Full Text] [Related]
14. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
15. Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated thyroid cancer: A Retrospective Study on a Korean Population.
Baek HS; Ha J; Kim K; Bae JS; Kim JS; Kim S; Lim DJ; Kim CM
Endocrinol Metab (Seoul); 2024 Apr; 39(2):310-323. PubMed ID: 38590123
[TBL] [Abstract] [Full Text] [Related]
16. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Wang H; Zhang C; Li Q; Tian T; Huang R; Qiu J; Tian R
BMC Cancer; 2024 Apr; 24(1):427. PubMed ID: 38589799
[TBL] [Abstract] [Full Text] [Related]
17. Factors associated with non-completion of palliative radiotherapy for spinal metastasis in patients with terminal cancer: a retrospective study.
Tokiya R; Nakanishi K; Okawaki M; Yamamoto A; Yamamoto Y; Saisho S; Fukuda Y; Nishie H; Teramoto S; Miyaji Y
Ann Palliat Med; 2024 Mar; 13(2):249-259. PubMed ID: 38584473
[TBL] [Abstract] [Full Text] [Related]
18. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory thyroid cancer Treated with Lenvatinib.
Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
[TBL] [Abstract] [Full Text] [Related]
20. The Japanese Breast cancer Society Clinical Practice Guidelines for Breast cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y; Yamauchi C; Toyama T; Nagai S; Sakai T; Kutomi G; Yoshimura M; Kawai M; Ohtani S; Kubota K; Nakashima K; Honma N; Yoshida M; Tokunaga E; Taira N; Iwata H; Saji S
Breast Cancer; 2024 May; 31(3):340-346. PubMed ID: 38570435
[TBL] [Abstract] [Full Text] [Related]
[Next]